Improved Gastrointestinal Symptoms and Quality of Life after Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients Receiving Tacrolimus.
10.3346/jkms.2010.25.12.1759
- Author:
Hyeon Seok HWANG
1
;
Bok Jin HYOUNG
;
Sol KIM
;
Ha Young OH
;
Yon Su KIM
;
Jung Kyung KIM
;
Yeong Hoon KIM
;
Yong Lim KIM
;
Chan Duck KIM
;
Gyu Tae SHIN
;
Chul Woo YANG
Author Information
1. Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. yangch@catholic.ac.kr
- Publication Type:Original Article ; Controlled Clinical Trial ; Multicenter Study ; Research Support, Non-U.S. Gov't
- Keywords:
Mycophenolate mofetil;
Enteric-coated mycophenolate sodium;
Tacrolimus;
Gastrointestinal Symptom;
Quality of Life;
Kidney Transplantation
- MeSH:
Adolescent;
Adult;
Aged;
Female;
Gastrointestinal Diseases/*chemically induced;
Graft Rejection/drug therapy;
Humans;
Immunosuppressive Agents/administration & dosage/*adverse effects/therapeutic use;
Kidney Failure, Chronic/therapy;
*Kidney Transplantation;
Male;
Middle Aged;
Mycophenolic Acid/administration & dosage/*adverse effects/*analogs & derivatives/therapeutic use;
Quality of Life;
Questionnaires;
Tablets, Enteric-Coated;
Tacrolimus/therapeutic use
- From:Journal of Korean Medical Science
2010;25(12):1759-1765
- CountryRepublic of Korea
- Language:English
-
Abstract:
It is reported that a conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) relieves gastrointestinal (GI) symptom burden and improves health-related quality of life (HRQoL). However, it is unclear whether renal transplant recipients using tacrolimus receive the same benefit from the conversion. In this prospective, multi-center, open-label trial, patients were categorized into two groups by their GI symptom screening. Equimolar EC-MPS (n=175) was prescribed for patients with GI burdens; those with no complaints remained on MMF (n=83). Gastrointestinal Symptom Rating Scale (GSRS) and Gastrointestinal Quality of Life Index (GIQLI) were evaluated at baseline and after one month. Patients and physicians completed Overall Treatment Effect (OTE) at one month. EC-MPS-converted patients had worse GSRS and GIQLI scores at baseline than MMF-continued patients (all P<0.001). Significant improvements in GSRS and GIQLI scores were observed for EC-MPS-converted patients at one month, but MMF-continued patients showed worsened GSRS scores (all P<0.05). OTE scale indicated that EC-MPS patients improved in overall GI symptoms and HRQoL more than MMF patients did (P<0.001). In tacrolimus-treated renal transplant recipients with GI burdens, a conversion from MMF to EC-MPS improves GI-related symptoms and HRQoL.
